AAAS: A Potent Drug Target and Biomarker for Neurological Disorders

Target Name: AAAS

NCBI ID: G8086

AAAS

AAAS: A Potent Drug Target and Biomarker for Neurological Disorders

AAAS (Adenosine A2A receptor antagonist) is a drug target and a biomarker that has been extensively studied in the field of neuroscience. AAAS is a highly selective adenosine A2A receptor antagonist that blocks the effects of adenosine, a molecule that plays a crucial role in pain modulation, anxiety, and inflammation.

AAAS is currently being investigated as a potential drug target for the treatment of various neurological disorders, including chronic pain, anxiety disorders, and neurodegenerative diseases. In addition, AAAS has also been shown to be a potential biomarker for several neurological disorders, making it an attractive candidate for diagnostic tools.

AAAS works by selectively blocking the A2A receptor, which is a G protein-coupled receptor that plays a key role in the regulation of pain, anxiety, and inflammation. The A2A receptor is involved in the production of pain signals and in the regulation of the immune response. By blocking the A2A receptor, AAAS reduces the effects of adenosine, allowing the body to better regulate its pain response and immune response.

One of the key advantages of AAAS is its high selectivity for the A2A receptor. This allows it to be used as a targeted drug, reducing the potential for unintended side effects associated with other drug classes. Additionally, AAAS has been shown to have a relatively long half-life, which allows for consistent dosing and improved patient compliance.

In addition to its potential use as a drug target, AAAS has also been shown to be a potential biomarker for several neurological disorders. For example, AAAS has been shown to be downregulated in the brains of individuals with anxiety disorders, and has been shown to be involved in the regulation of pain perception. Additionally, AAAS has been shown to be decreased in individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

AAAS has also been shown to be involved in the regulation of the immune response, which is a crucial aspect of neurodegenerative diseases. For example, AAAS has been shown to be involved in the regulation of the production of immune cells that contribute to the development of neurodegenerative diseases. Additionally, AAAS has been shown to be involved in the regulation of the immune response, which is crucial for the regulation of autoimmune diseases.

In conclusion, AAAS is an attractive drug target and biomarker due to its high selectivity for the A2A receptor, its relatively long half-life, and its potential role in the regulation of pain, anxiety, and inflammation. Further research is needed to fully understand the potential clinical applications of AAAS, including its potential efficacy and safety as a drug and its potential as a biomarker for neurological disorders.

Protein Name: Aladin WD Repeat Nucleoporin

Functions: Plays a role in the normal development of the peripheral and central nervous system (PubMed:11062474, PubMed:11159947, PubMed:16022285). Required for the correct localization of aurora kinase AURKA and the microtubule minus end-binding protein NUMA1 as well as a subset of AURKA targets which ensures proper spindle formation and timely chromosome alignment (PubMed:26246606)

The "AAAS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AAAS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets